Sparks of Inhalation Innovation

Recommendations

Info

Introducing Mobius ® 2000 L Single-use Bioreactor. Ease of use with an innovative twist. The world’s first bioreactor with a pull-out drawer for quick, easy loading. That’s just the first of many innovations: - Self-inflating bag, with built in baffle for homogeneous mixing, eliminates the need for operator intervention during inflation. - 5:1 turndown ratio provides the most flexible seeding and growth strategy. - Intuitive, simple-to-navigate software reduces the learning curve for operators and allows for easy integration into your plant automation strategy. www.merckmillipore.com/mobiustwist Buffers Mixers Cell Culture Media Clarification Services Mobius ® 2000 L Single-use Bioreactor Merck Millipore is a business of Merck Millipore, the M logo and Mobius are registered trademarks of Merck KGaA, Darmstadt, Germany. © 2015 EMD Millipore Corporation, Billerica, MA USA. All rights reserved. AD1419EN00 Rev A. 06/2015
M&A Merry-Go-Round Round and round she goes, where she stops nobody knows. Editorial M ylan’s long-running takeover bid for Perrigo has failed. After a pitched battle – sometimes descending into outright name-calling – Perrigo fended off Mylan for good. The Mylan-Perrigo story is just a tiny sample of the merger and acquisition (M&A) fever that has gripped the industry over the past few years. Indeed, scores of companies have been racing to secure the best partnerships, hoping to boost growth and fill pipelines. Some companies are pushing for mergers that don’t simply add to their businesses, but instead transform them; an obvious example is Allergan (formerly Actavis). Originally a generics maker, its 2014 buyout of Allergan and subsequent divestment of the original Actavis ‘legacy’ generics business, has enabled its reinvention as a specialty drugs pharmaceutical company. Now there is talk of selling the company to Pfizer in a $100 billion deal... Where will the M&A juggernaut stop? Will bigger companies swallow up their rivals, until only the strongest – or leanest – survive? Or will falling share prices and tightening tax loopholes eventually dampen enthusiasm amongst investors for corporate mega-mergers? In either case, the current M&A fever will burn out eventually, but what will the outcome be for the industry, its workers and the wider population? In the short-term, takeover bids are rarely good news for drug company employees. Mylan are downplaying the significance of the bungled Perrigo takeover – and though no one likes to fail, another deal will almost certainly come along soon enough. Meanwhile, celebrations at Perrigo are likely to be short-lived for some, given that the company has pledged to cut 800 jobs in the coming months. It remains to be seen whether all this M&A will leave the industry better off in the long term. Could it be that by reducing diversity, the industry risks the very thing on which its survival depends – innovation? The increasing trend towards ‘buying in’ innovation may be necessary to counteract failing pipelines, but if a pharma company is no longer creating new drugs, does it lose something fundamental to its identity? And how will the drug discovery ecosystem cope with that shift? The last round of mega-mergers, at the turn of the millennium, did little to solve big pharma’s pipeline woes…will today’s newly minted deals fare any better? Charlotte Barker Editor
Page 1 and 2: NOVEMBER 2015 # 13 Upfront Can oral
Page 3 and 4: Online this Month Will You Enter th
Page 5: 11:15 47 Best Practice 36 When Outs
Page 9 and 10: FDA’s Identification of Extractab
Page 11 and 12: Upfront 11 are injected because th
Page 13 and 14: Upfront 13 Breaking Bad Language C
Page 15 and 16: Upfront 15 crystal structures (pol
Page 17 and 18: Upfront 17 Nobel Prize for Noble C
Page 19 and 20: In My View 19 “The findings of o
Page 21 and 22: In My View 21 Bacteria confer many
Page 24 and 25: Smarter Inhalers Electronic monitor
Page 26 and 27: Pre-Filled Challenges I’ve noted
Page 28 and 29: 28 Feature “Some developments are
Page 30 and 31: 30 The Medicine Maker × GE Health
Page 32 and 33: Overcoming Production Bottlenecks I
Page 34 and 35: Nominations for the 2016 Humanity i
Page 36 and 37: 36 Best Practice When Outsourcing G
Page 38 and 39: 38 Best Practice The CMO Checklist
Page 40 and 41: 40 The Medicine Maker × Thermo Fi
Page 42 and 43: SIGN UP NOW FOR FREE 1. App Get an
Page 44 and 45: 44 Business The Journey from Chemi
Page 46 and 47: 46 Business “I can honestly say
Page 48 and 49: 48 Business • Advance of informa
Page 50 and 51: The Receptive Regulator Sitting Dow
Page 52: new optiform ‰ solution suite enh

Sparks of Inhalation Innovation

Create successful ePaper yourself

Delete template?

Save as template?